Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a biotechnology company centered on DehydraTECH™, a patented oral drug delivery formulation and processing platform. Company news releases highlight ongoing research and development programs where DehydraTECH is evaluated with active pharmaceutical ingredients such as GLP-1 drugs and cannabidiol (CBD), as well as updates on licensing, partnerships and capital markets activity.
Investors following LEXX news can expect detailed coverage of clinical and preclinical study results, particularly in the GLP-1 sector. Recent announcements describe human pilot studies and a registered Phase 1b study in Australia that compare DehydraTECH-based oral formulations of semaglutide, tirzepatide and liraglutide against existing injectable or oral reference products. These updates often include information on safety, tolerability, adverse events, blood glucose and HbA1c changes, body weight, biodistribution and blood pressure outcomes.
Lexaria’s news flow also includes strategic and business development updates, such as the extension of a Material Transfer Agreement with a pharmaceutical company evaluating DehydraTECH, the engagement of a global life science business development advisory firm, and commentary on how new data sets are being used to guide future R&D plans. In addition, the company regularly reports on financing transactions via registered direct offerings and private placements, describing how proceeds are intended to support research, working capital and general corporate purposes.
For readers tracking LEXX, this news page provides a centralized view of the company’s scientific progress, intellectual property developments, partnership discussions and funding activities related to its DehydraTECH platform.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has announced its first patent grant in India, expanding its intellectual property portfolio to a total of 19 patents worldwide. This new patent, titled Stable ready-to-drink beverage compositions comprising lipophilic active agents, is valid for 20 years from December 1, 2016. The patent enhances Lexaria's existing protections in the EU, U.S., and Australia, allowing innovation in ready-to-drink beverages that include various active ingredients like NSAIDs and cannabinoids. Lexaria's patented technology, DehydraTECH™, improves the bio-absorption of these compounds.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced favorable results from its first animal study and the initiation of its first human clinical study as part of its 2021 Hypertension R&D program. CEO Chris Bunka will present at the Benzinga Global Small Cap Conference on May 13, 2021, at 3:50 p.m. ET. The presentation will cover Lexaria's DehydraTECH™ drug delivery technology and its effectiveness in enhancing the delivery of cannabidiol (CBD) for hypertension and other applications. The event aims to connect small-cap companies with investors.
Lexaria Bioscience Corp. (NASDAQ:LEXX, NASDAQ:LEXXW) announced successful results from its 2021 study HYPER-A21-1, showcasing its DehydraTECH 2.0 formulations. These new formulations delivered up to 2,178% more CBD into the bloodstream and 1,737% more into brain tissue compared to a standard MCT oil control. The study involved ten rats receiving a 25 mg/Kg dose of CBD over 120 minutes. CEO Chris Bunka emphasized the substantial absorption efficiency of these formulations, which are anticipated to have applications in both pharmaceutical and consumer product markets.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has launched its human clinical hypertension study HYPER-H21-1, examining the effectiveness of its patented DehydraTECH CBD formulation in controlling blood pressure. The study involves 24 volunteers and aims to complete dosing within weeks, with preliminary results expected by July. Secondary objectives include assessing the absorption rate of CBD and related metabolites. Lexaria has 18 granted patents and anticipates further studies to support DehydraTECH's validity as a hypertension treatment. Final results are scheduled for early September 2021.
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) announces the appointment of Gregory Downey as the new Chief Financial Officer effective April 15, 2021. Downey, previously the Company's Controller, brings over ten years of CFO experience and will be compensated with a CDN$144,000 annual salary, a 10% increase, and stock options. The Company also plans to issue 300,000 share purchase warrants to third-party consultants, exercisable until April 16, 2024, at US$9.00 per share. Lexaria continues to advance its DehydraTECH technology for improved drug delivery.
Lexaria Bioscience Corp. (NASDAQ:LEXX) announced that its client Amari Corp.'s "Everyday Calm" CBD product was recognized as a Top CBD Product Pick by New Hope Network during the Natural Products Expo 2020. This accolade underscores the effectiveness of Lexaria's DehydraTECH technology, which enhances CBD delivery for improved consumer satisfaction. The DehydraTECH platform demonstrates a potential increase in bio-absorption by up to 10x, essential for the growth of CBD products in retail. Lexaria aims to expand the reach of its technology across multiple product formats.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announced its largest-ever R&D initiative for 2021, targeting four drug markets with a potential value of $87 billion. The studies will focus on enhancing delivery systems for NSAIDs, THC, nicotine, and sildenafil using the DehydraTECH technology. Key market insights include the NSAID market expected to grow to $24.4 billion by 2027 and the cannabis market projected at $40.6 billion by 2024. These initiatives aim to improve drug absorption and speed, with test articles scheduled for manufacturing and dosing in the coming months.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced successful stability testing for its DehydraTECHTM CBD-infused beverages, revealing a remarkable 93.4% potency retention one year post-production. This ensures excellent microbial purity and consistent CBD distribution without physical mixing, addressing common beverage degradation challenges. The technology, which significantly enhances cannabinoid absorption, is poised for broader applications, and Lexaria continues its industry leadership in innovative drug delivery systems.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) is advancing its hypertension research and development program, which includes three human clinical studies and two animal studies, alongside two antiviral drug evaluations. CEO Chris Bunka will present at the Benzinga Biotech Small Cap Conference on March 24, 2021, at 9:45 AM ET, detailing the company's DehydraTECH drug delivery technology aimed at improving the bio-absorption of active pharmaceutical ingredients. Lexaria holds 18 granted patents and approximately 60 pending, positioning itself strongly in the biotech sector.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) reports progress in two of four planned antiviral studies using its DehydraTECH™ technology targeting SARS-CoV-2. The studies assess the effectiveness of enhanced formulations of antiviral drugs, including Remdesivir, in animal and human cell cultures. Results from the animal study (VIRAL-A20-2) are expected by late May, while human cell evaluations (VIRAL-C21-3) will commence in April, with results anticipated in June. The entire research initiative is fully funded and aims for regulatory approvals and commercial partnerships.
FAQ
What is the current stock price of Lexaria Bioscience (LEXX)?
What is the market cap of Lexaria Bioscience (LEXX)?
